AFFiRiS AG Presents Early Clinical Data On A First-Of-Its-Kind Parkinson's Disease Vaccine
7/24/2014 10:17:58 AM
AFFiRiS AG, Vienna, Austria will present data from a Phase I clinical trial of PD01A, a vaccine approach that aims to slow or stop Parkinson’s disease progression. The Michael J. Fox Foundation supported the study with a $ 1.5 million grant and will discuss the impact of the results for patients and the Parkinson’s research community.
Thursday, July 31, 2014
11.00 am EST (Eastern Standard Time)
03.00 pm UTC (Coordinated Universal Time)
New York Marriott East Side Hotel
525 Lexington Ave, New York
Room Morgan A
Live webcast link: http://totalwebcasting.com/view/?id=affiris
Walter Schmidt, PhD: CEO & Co-founder, AFFiRiS AG Todd Sherer, PhD: CEO, The Michael J. Fox Foundation Prof. Achim Schneeberger, MD: CMO, AFFiRiS AG
Till Jelitto or Martina Herrmann-Thurner PR&D - Public Relations for Research & Education
+43 1 505 70 44
firstname.lastname@example.org or email@example.com
If you are unable to attend the press conference, please visit the aforementioned web link for a live webcast. An embedded message board will allow you to participate in the Q&A. A recording of the conference will be made available immediately after the press conference at http://totalwebcasting.com/view/?id=affiris
About AFFiRiS AG
Based on the company's own patent positions, AFFiRiS develops tailor-made peptide vaccines (and more) for Alzheimer's disease, Atherosclerosis, Parkinson's disease, diabetes and several other conditions with urgent requirement for new treatments and attractive market volumes. Alzheimer's is the current lead indication. AFFiRiS currently employs 100 highly-qualified staff at the Campus Vienna Biocenter in Vienna, Austria (www.affiris.com).
About The Michael J. Fox Foundation for Parkinson’s Research As the world’s largest nonprofit funder of Parkinson’s research, The Michael J. Fox Foundation is dedicated to accelerating a cure for Parkinson’s disease and improved therapies for those living with the condition today. The Foundation pursues its goals through an aggressively funded, highly targeted research program coupled with active global engagement of scientists, Parkinson’s patients, business leaders, clinical trial participants, donors and volunteers. In addition to funding more than $450 million in research to date, the Foundation has fundamentally altered the trajectory of progress toward a cure. Operating at the hub of worldwide Parkinson’s research, the Foundation forges groundbreaking collaborations with industry leaders, academic scientists and government research funders; increases the flow of participants into Parkinson’s disease clinical trials with its online tool, Fox Trial Finder; promotes Parkinson’s awareness through high-profile advocacy, events and outreach; and coordinates the grassroots involvement of thousands of Team Fox members around the world.
Help employers find you! Check out all the jobs and post your resume.
comments powered by